Online citations, reference lists, and bibliographies.
← Back to Search

Comparison Of The Stability Of Technetium-labeled Peptides To Challenge With Cysteine.

M. Stalteri, S. Bansal, R. Hider, S. Mather
Published 1999 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
We have labeled a series of short peptides with technetium-99m either by direct labeling at pH 11 or by exchange from [99mTc]technetium glucoheptonate. Typical labeling yields obtained were as follows: N-acetyl-Gly-Cys(S-Acm)-Gly-Cys(S-Acm)-Gly-NH2 (Acm = acetamidomethyl) 99%, S-benzoyl-mercaptoacetyltriglycine (S-Benzoyl-MAG3) 95%, mercaptoacetyldiglycine-NH2 (MAG2-NH2) 94%, MAG3 92%, N-acetyl-Aib-Aib-Cys-NH2 (Aib = aminoisobutyric acid) 91%, Gly-Gly-Gly-Gly 90%, N-acetyl-Gly-Gly-Cys-Gly 87%, cyclo-1, 4-(Gly-Gly-Gly-Gln) 40%, S-methyl-MAG2-NH2 0%. In the absence of cysteine, all of the labeled peptides were quite stable in solution, with at least 80-90% of the labeled peptide remaining at 24 h. The order of stability of the labeled peptides to challenge with cysteine was found to be MAG3 > S-benzoyl-MAG3 > N-acetyl-Gly-Cys(S-Acm)-Gly-Cys(S-Acm)-Gly-NH2 >N-acetyl-Aib-Aib-Cys-NH2 > MAG2-NH2 > N-acetyl-Gly-Gly-Cys-Gly > cyclo-1,4-(Gly-Gly-Gly-Gln) > Gly-Gly-Gly-Gly. The peptides without a sulfur donor were least stable to challenge with cysteine.

This paper is referenced by
Technetium-99m-Labeled N-(2-Hydroxypropyl) Methacrylamide Copolymers: Synthesis, Characterization, and in Vivo Biodistribution
A. Mitra (2004)
Antibody directed enzyme prodrug therapy - a mechanistic approach.
R. Francis (2005)
In vitro and in vivo characterization of an interleukin‐15 antagonist peptide by metabolic stability, 99mTc‐labeling, and biological activity assays
Y. Rodríguez-Álvarez (2018)
Synthesis and 99mTc‐labelling of bz‐MAG3‐triprolinyl‐peptides, their radiochemical evaluation and in vitro receptor‐binding
G. Domselaar (2000)
Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments.
D. Berndorff (2006)
Solid phase preparations of 99mTc labeled radiopharmaceuticals
P. S. Rao (2002)
Preparation and in vitro and in vivo evaluation of technetium-99m-labeled folate and methotrexate conjugates as tumor imaging agents.
S. Okarvi (2006)
Synthesis and antimicrobial evaluation of two peptide LyeTx I derivatives modified with the chelating agent HYNIC for radiolabeling with technetium-99m
L. L. Fuscaldi (2016)
M. Taner (2018)
99mTc-labeling and molecular modeling of short dipeptide glycyl-l-proline
R. Staník (2011)
Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)–carbonyl complex
R. Waibel (1999)
Radiolabelling of glycosylated MFE-23::CPG2 fusion protein (MFECP1) with 99mTc for quantitation of tumour antibody-enzyme localisation in antibody-directed enzyme pro-drug therapy (ADEPT)
R. Francis (2004)
Utilizing an experimental and computational approach to ligand design for chelating oxorhenium(V) and oxotechnetium(V)
D. Demoin (2014)
Evaluation of 99mTc-MAG3-annexin V: influence of the chelate on in vitro and in vivo properties in mice.
J. Vanderheyden (2006)
Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors.
S. Okarvi (2010)
99mTc radiolabeled archaeosomes as a potential melanoma imaging agent
Pablo Cabral (2018)
Different chelators and different peptides together influence the in vitro and mouse in vivo properties of 99Tcm
T. Qu (2001)
99mTc-labeling and in vitro characterization of N4- and N3S-RGDS-derivative peptides
A. Perera Pintado (2008)
99mTc Nanocoll: a radiopharmaceutical for sentinel node localisation in breast cancer--in vitro and in vivo results.
G. Gommans (2009)
Site-specifically modified fusion proteins for molecular imaging.
H. Wang (2008)
Semantic Scholar Logo Some data provided by SemanticScholar